Stocks
Atea Pharmaceuticals, Inc.AVIR
NASDAQHealthcareBiotechnology$4.39
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing antiviral therapeutics, with its lead candidate, bemnifosbuvir, targeting hepatitis C and COVID-19. Investors track AVIR for its phase 3 data readouts and potential in the antiviral market.
52W Range: $2.87-$6.45
Congressional Interest in Atea Pharmaceuticals, Inc. (AVIR)
No congressional trades have been disclosed for Atea Pharmaceuticals, Inc. (AVIR) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading AVIR?
No congressional trades found for this stock.